In a statement of correction issued Friday, Star Scientific claims to have "underreported" results from a phase II study investigating the effect of Anatabine on C-reactive protein (CRP), a biomarker for inflammation.
On Wednesday, Star Scientific said CRP levels dropped in 26% of diabetic patients taking Anatabloc for a month. On Friday, however, the company claimed CRP levels had actually dropped in 61% of diabetic patients.
Star Scientific's performed the same magical upsizing on results for the non-diabetic patients in the study, with CRP responses improving from 12% on Wednesday to 38% on Friday.The company offered no explanation Friday for how or why the data from the study allegedly improved over the course of two days. Without an explanation, it's impossible to know which data are false and which are true. Let's hope someone at the Securities and Exchange Commission gets some answers. -- Reported by Adam Feuerstein in Boston. Follow @AdamFeuerstein
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV